Tetraphase Pharmaceuticals Inc. (TTPH) Trading Up 4.3%
Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) shares were up 4.3% during trading on Tuesday . The stock traded as high as $4.25 and last traded at $4.17, with a volume of 452,481 shares. The stock had previously closed at $4.00.
Several research analysts recently commented on TTPH shares. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research note on Wednesday, July 6th. Wedbush reissued a “buy” rating on shares of Tetraphase Pharmaceuticals in a research note on Saturday, May 14th. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Saturday, May 14th. Finally, Gabelli cut Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $7.00 target price for the company. in a research note on Friday, May 13th. Twelve investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and an average target price of $14.85.
The firm’s 50 day moving average is $4.12 and its 200-day moving average is $4.39. The stock’s market capitalization is $143.86 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.01. The company earned $1.20 million during the quarter, compared to analyst estimates of $2.05 million. The company’s revenue for the quarter was down 63.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.72) earnings per share. On average, analysts anticipate that Tetraphase Pharmaceuticals Inc. will post ($1.98) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Tetraphase Pharmaceuticals stock. California Public Employees Retirement System increased its stake in shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 1,459.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 276,000 shares of the biopharmaceutical company’s stock after buying an additional 258,300 shares during the period. California Public Employees Retirement System owned approximately 0.76% of Tetraphase Pharmaceuticals worth $2,768,000 as of its most recent filing with the SEC.
Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.